Eli Lilly's phase 1 amylin data impress analysts, pairing 11% weight loss with tolerable profile

Eli Lilly's phase 1 data for amylin analog eloralintide showed promising weight loss results, up to 11.3% in 12 weeks, fueling speculation it could be combined with Zepbound to create a market-leading obesity treatment. Analysts from Cantor Fitzgerald and Jefferies view the data favorably, suggesting eloralintide could be a key component of Lilly's next-generation obesity drug. However, questions remain about the long-term efficacy and tolerability of amylin analogs, with Zealand Pharma suggesting a broader receptor approach may be necessary for sustained weight loss.

Analysis

Eli Lilly's Phase 1 data for its amylin analog, eloralintide, shows significant potential in the highly competitive obesity market, delivering weight loss of up to 11.3% over 12 weeks. The results have been viewed favorably by analysts at Cantor Fitzgerald and Jefferies, who speculate that a combination of eloralintide with Lilly's existing GLP-1/GIP drug, tirzepatide (Zepbound), could become a market-leading successor therapy. A key advantage noted is the drug's tolerability profile, with relatively low rates of gastrointestinal side effects (10% diarrhea) compared to GLP-1 agonists. However, significant uncertainties remain. The data is early-stage, and the durability of weight loss beyond 12 weeks is unproven, a point of contention raised by the CEO of competitor Zealand Pharma, who advocates for a multi-receptor approach for sustained efficacy. Furthermore, crucial data from a Phase 1 study combining eloralintide with tirzepatide, initiated in April, is still pending. This development occurs as rivals like Novo Nordisk advance their own amylin combination (CagriSema) and companies such as AbbVie and Roche enter the field through substantial acquisitions.

Key Decisions for Investors

• Investors should view this data as a positive long-term reinforcement of Eli Lilly's R&D pipeline in the lucrative obesity space, but recognize that a potential combination therapy is still in early development and years from commercialization.
• Monitor key upcoming catalysts for eloralintide, specifically the full data presentation at the American Diabetes Association conference on June 22 and the future release of results from the pivotal eloralintide-tirzepatide combination study.
• Maintain a keen awareness of the competitive landscape, paying close attention to the progress of Novo Nordisk's CagriSema and emerging data on alternative mechanisms, such as the multi-receptor approach discussed by Zealand Pharma, which could challenge Lilly's strategy.